Provided is an antibody-drug conjugate which can be used as an anti-tumor agent, said conjugate being characterized by being produced by binding an anti-tumor compound represented by formula (1) to an antibody through a linker having a structure represented by the formula: -L1-L2-LP-NH-(CH2)n1-La-Lb-Lc- (wherein the antibody is bound at the terminal of L1, and the anti-tumor compound is bound at the terminal of Lc in which the binding site of the anti-tumor compound is a nitrogen atom in an amino group located at position-1).